Susan Krumplitsch represents life science companies in intellectual property disputes, with an emphasis on Hatch-Waxman, BPCIA and trade secret litigation. Her clients include innovative biotechnology, pharmaceutical and medical device companies and she regularly appears in federal courts across the country and in post-grant review proceedings at the US Patent and Trademark Office.
Her practice involves a wide variety of technologies, including therapeutic monoclonal antibodies, pharmaceutical formulations, small molecule drug compounds, next-generation DNA sequencing, mammalian cell lines, biofuels, fungicides and magnetic resonance angiography. Susan's trial experience includes bench and jury trials in federal courts, oral arguments at the Patent Trial and Appeal Board (PTAB), hearings before the International Trade Commission and domestic arbitrations.
She also has significant pro bono experience representing asylum applicants and drafting amicus briefs for various US Circuit Courts of Appeal and the Supreme Court of the United States.
Unsolicited e-mails and information sent to DLA Piper or the independent DLA Piper Relationship firms will not be considered confidential, may be disclosed to others, may not receive a response, and do not create a lawyer-client relationship with DLA Piper or any of the DLA Piper Relationship firms. Please do not include any confidential information in this message. Also, please note that our lawyers do not seek to practice law in any jurisdiction in which they are not properly permitted to do so.